SE9300246D0 - New carbohydrate-based anti-inflammatory agents - Google Patents

New carbohydrate-based anti-inflammatory agents

Info

Publication number
SE9300246D0
SE9300246D0 SE9300246A SE9300246A SE9300246D0 SE 9300246 D0 SE9300246 D0 SE 9300246D0 SE 9300246 A SE9300246 A SE 9300246A SE 9300246 A SE9300246 A SE 9300246A SE 9300246 D0 SE9300246 D0 SE 9300246D0
Authority
SE
Sweden
Prior art keywords
inflammatory agents
based anti
new carbohydrate
elam
assay
Prior art date
Application number
SE9300246A
Other languages
English (en)
Swedish (sv)
Inventor
Brian K Brandley
Michael Tiemeyer
Stuart J Swiedler
Margaret Moreland
Hans Schweingruber
Original Assignee
Glycomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/559,856 external-priority patent/US5211936A/en
Priority claimed from US07/637,868 external-priority patent/US5143712A/en
Application filed by Glycomed Inc filed Critical Glycomed Inc
Publication of SE9300246D0 publication Critical patent/SE9300246D0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SE9300246A 1990-07-30 1993-01-27 New carbohydrate-based anti-inflammatory agents SE9300246D0 (sv)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/559,856 US5211936A (en) 1990-07-30 1990-07-30 Method of determining a cite of inflammation utilizing elam-1 ligands site
US61311390A 1990-11-15 1990-11-15
US07/637,868 US5143712A (en) 1990-07-30 1991-01-07 Method of determining a site of inflammation utilizing elam-1 ligands
US07/683,458 US5211937A (en) 1990-07-30 1991-04-11 Method of determining a site of inflammation utilizing elam-1 ligands
PCT/US1991/005416 WO1992002527A1 (en) 1990-07-30 1991-07-30 New carbohydrate-based anti-inflammatory agents

Publications (1)

Publication Number Publication Date
SE9300246D0 true SE9300246D0 (sv) 1993-01-27

Family

ID=27504808

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9300246A SE9300246D0 (sv) 1990-07-30 1993-01-27 New carbohydrate-based anti-inflammatory agents

Country Status (7)

Country Link
US (2) US5211937A (ja)
EP (1) EP0541719A4 (ja)
JP (1) JPH06500330A (ja)
AU (1) AU657275B2 (ja)
CA (1) CA2088489A1 (ja)
SE (1) SE9300246D0 (ja)
WO (1) WO1992002527A1 (ja)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576305A (en) * 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
WO1992009293A1 (en) 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5374655A (en) * 1991-06-10 1994-12-20 Alberta Research Council Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
CA2110495A1 (en) * 1991-06-10 1992-12-23 Robert M. Ippolito Immunosuppressive and tolerogenic oligosaccharide derivatives
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
GB9114657D0 (en) * 1991-07-06 1991-08-21 Antisoma Ltd Diagnostic compounds
US5332575A (en) * 1991-10-03 1994-07-26 Parfums Christian Dior Method of targeting melanocytes with a compound containing a fucose residue
US5326752A (en) * 1991-11-27 1994-07-05 Glycomed Incorporated Substituted lactose and lactosamine derivatives as cell adhesion inhibitors
JPH05247078A (ja) * 1992-03-03 1993-09-24 Japan Tobacco Inc 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体
CA2132518A1 (en) * 1992-03-20 1993-09-30 Uma Sinha Glycosylation-mediated inhibition of factor x
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
WO1993024526A1 (en) * 1992-05-28 1993-12-09 Centocor, Inc. Peptide inhibitors of selectin binding
JPH08504171A (ja) * 1992-05-28 1996-05-07 セントコー・インコーポレーテッド セレクチン結合のペプチド阻害剤
CA2100412A1 (en) * 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
WO1994005310A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of cellular adhesion
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5695752A (en) * 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
AU4859793A (en) * 1992-09-11 1994-04-12 Regents Of The University Of California, The Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
AU686116B2 (en) * 1992-10-02 1998-02-05 Alberta Research Council Inc. Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US6406894B1 (en) 1992-12-11 2002-06-18 Glycorex Ab Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
WO1994020514A1 (en) * 1993-03-04 1994-09-15 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
US5811404A (en) * 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5854218A (en) * 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
JPH08510729A (ja) * 1993-05-14 1996-11-12 サイテル コーポレイション 細胞接着のインヒビターとしてのシアリルＬｅ▲上ｘ▼類似体
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
JP3662021B2 (ja) 1993-05-17 2005-06-22 アーヴァント イミュノセラピューティクス インコーポレイテッド 補体関連蛋白質および炭水化物よりなる組成物、ならびに該組成物の製法および使用方法
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) * 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
AU698176B2 (en) * 1993-07-28 1998-10-29 Cis Bio International Radiolabelled glucans
US5350748A (en) * 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
US5783693A (en) * 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
AU709149B2 (en) * 1994-03-02 1999-08-19 Neose Technologies, Inc. Method for treating and inhibiting gastric and duodenal ulcers
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
HUT77345A (hu) * 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
EP0759758A4 (en) * 1994-05-18 1997-05-14 Glycomed Inc MEDICINES BASED ON SIALIC ACID / FUCOSIS
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
CA2209084A1 (en) * 1994-12-28 1996-07-04 Hiroshi Miyauchi Lewis x derivative and process for producing the same
US5571796A (en) * 1995-06-06 1996-11-05 Alberta Research Council Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
AU6485496A (en) 1995-07-14 1997-02-18 Glycotech Corp. Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
CZ89098A3 (cs) * 1995-09-29 1998-09-16 Glycim Oy Syntetické polylaktosaminy obsahující až multivalentní sLEX a metody pro jejich použití
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US6191271B1 (en) 1997-09-05 2001-02-20 Glycim Oy Synthetic divalent sLex containing polylactosamines and methods for use
US6245902B1 (en) * 1999-08-09 2001-06-12 University Of Iowa Research Foundation C-glycoside analogs and methods for their preparation and use
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030045461A1 (en) 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
CA2486106C (en) * 2002-05-16 2013-07-16 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
CA2490703A1 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
CA2546784A1 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
EP1763533B1 (en) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Specific antagonist for both e- and p-selectins
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
CN101291946B (zh) * 2005-08-09 2011-06-29 糖模拟物有限公司 对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂
LT2264043T (lt) * 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
DE102006046952A1 (de) * 2006-10-04 2008-04-10 Ley, Fritz, Dr. Dentale, insbesondere remineralisierende und gegen schmerzempfindliche Zähne wirksame Zusammensetzung sowie dentale Partikel, insbesondere für die Zusammensetzung
EP2074132B1 (en) * 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
NZ598863A (en) * 2007-02-09 2013-11-29 Glycomimetics Inc Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
ES2426784T3 (es) * 2008-06-13 2013-10-25 Glycomimetics, Inc. Tratamiento de cánceres de la sangre usando compuestos glicomiméticos seleccionados
KR101098581B1 (ko) * 2009-01-09 2011-12-26 서울대학교산학협력단 Ａｂｈ 항원을 이용한 염증질환 개선용 조성물
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
WO2010126888A1 (en) * 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA2858099C (en) 2011-12-22 2020-12-15 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
DK2928476T3 (en) 2012-12-07 2018-05-22 Glycomimetics Inc RELATIONSHIPS, COMPOSITIONS AND METHODS OF USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS
DK3227310T3 (da) 2014-12-03 2019-09-30 Glycomimetics Inc Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3091454A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330299A (en) * 1981-03-09 1982-05-18 Evreka, Inc. Article and method for measuring glucose level in body fluids
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5011920A (en) * 1986-01-30 1991-04-30 Fred Hutchinson Cancer Research Center Disialofucoganglioside immunogen and fucoganglioside monosialosyl Lea II
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
AU8007791A (en) * 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators

Also Published As

Publication number Publication date
CA2088489A1 (en) 1992-01-31
US5470842A (en) 1995-11-28
WO1992002527A1 (en) 1992-02-20
AU657275B2 (en) 1995-03-09
EP0541719A1 (en) 1993-05-19
AU8510791A (en) 1992-03-02
EP0541719A4 (en) 1995-09-06
JPH06500330A (ja) 1994-01-13
US5211937A (en) 1993-05-18

Similar Documents

Publication Publication Date Title
SE9300246D0 (sv) New carbohydrate-based anti-inflammatory agents
NO903762L (no) Fremgangsmaate for aa opprette diffusjonsbinding mellom korrosjonsbestandige materialer.
DE69115185D1 (de) Arbeitsmittelzusammensetzung für Kältemaschinen.
DE69329667D1 (de) Arbeitsflüssigkeitszusamensetzung für Kältemaschine
DE69535272D1 (de) Polyspezifische immunkonjugate und antikörper zusammensetzungen zur zielgerichteten erkennung des multidrug resistenz phenotyps
DK0925073T3 (da) Staphylococcus aureus antigen
DE3786851D1 (de) Feststellung des endpunktes beim graben-aetzen durch laserinduzierte fluoreszenz.
ATE79372T1 (de) Markierte antikoerperfragmente.
NO801557L (no) Leddet lastearm for fluider.
DE69939171D1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
DE3483082D1 (de) Zusammensetzungen fuer toilettenartikel.
FI95484C (fi) Menetelmä näytteessä olevan metallin määrittämiseksi
DE3863517D1 (de) Verwendung von polyaralkylaminen als korrosionsinhibitoren.
DE68925923D1 (de) Antigene der einzigen Spaltungsstelle von Fibrinogen durch Elastase
FR2498062B1 (fr) Ensemble portatif a usages multiples, notamment pour le pique-nique
DK157374C (da) Remstrammer med fluidumdaempningsorgan
NO902222L (no) Roerkopling med gjenget tetning i ugjenget hulrom.
IT1120406B (it) Indicatori di fluorescenza per l'impiego nella cromatografia e mezzi di assorbimento che li contengono
IT1153659B (it) Procedimento per la bainitizzazione isotermica, almeno parziale, di pezzi in materiali ferrosi
ATA778479A (de) Verwendung von feuerfesten betonfertigteilen fuer die zustellung von hochoefen
FR2534461B1 (fr) Table de travail pour cuisine, laboratoire et similaire
DE69007149D1 (de) Metallbearbeitungsölzusammensetzung.
ATA188885A (de) Rohrhalterung, insbesondere fuer abwasserrohre
IT8423720A0 (it) Pezzo, specialmente di materiali ferrosi fusi.
AT379226B (de) Lampe, insbesondere fuer friedhoefe